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Abstract 
Background: Polypharmacy, the simultaneous taking of many medications, 
has been well documented and is a topic of much concern for those looking to 
improve the quality of care for the elderly. Elderly patients often develop 
complicated and multi-factorial health states that require extensive 
pharmacotherapy, leaving this population at risk for exposure to drug-drug 
interactions and other adverse events. Previous literature supports an association 
between an increase in the rate of adverse events as the number of drugs taken by 
a patient increases. 
Objective: We sought to evaluate the prevalence of polypharmacy, and to 
determine patient characteristics that are predictive of exposure to polypharmacy, 
in the elderly population of the Emilia-Romagna region in Italy. 
Methods: We conducted a retrospective cohort study of the 2007 Emilia-
Romagna outpatient pharmacy database linked with patient information available 
from a demographic file of approximately 1 million Emilia-Romagna residents 
aged ≥65 years. The cohort was comprised of 887 165 elderly subjects who had 
at least one prescription filled during the study year. Using the World Health 
Organization’s defined daily dose (DDD) to determine the duration of treatment 
for a given drug, we defined a polypharmacy episode as overlapping treatment 
with five or more medications occurring for at least one day. The prevalence of 
polypharmacy was measured together with subject characteristics found to be 
predictive of polypharmacy exposure.  
Results: A total of 349 689 elderly people in the population (39.4%) were 
exposed to at least one episode of polypharmacy during the study period. The 
prevalence of polypharmacy substantially increased with age and with a higher 
number of chronic conditions. Over 35% of those exposed to polypharmacy were 
exposed for 101 or more days of the year. The top three classes of medications 
involved in polypharmacy were antithrombotics, peptic ulcer disease and gastro-
oesophageal reflux disease agents and ACE inhibitors. The odds of exposure to 
polypharmacy were higher for older subjects, males and subjects living in urban 
areas. 
Conclusions: This study provides evidence that the prevalence of 
polypharmacy in the elderly in Emilia-Romagna is substantial. Educational 
programmes should be developed to inform clinicians about the magnitude of the 
polypharmacy phenomenon and the patient characteristics associated with 
polypharmacy. Raising physicians’ awareness of polypharmacy may help to 
ensure safe, effective and appropriate use of medication in the elderly. 
 
Introduction 
Polypharmacy, the simultaneous taking of many medications, has been well 
documented in the US and Europe.[1-3] It is a topic of much concern for those 
looking to improve the quality of care for the elderly, as patients in this 
population often develop complicated and multi-factorial health states. As the 
incidence of chronic disease increases, so does the need for pharmacotherapy.[2,4] 
This inherently places the elderly at risk of exposure to polypharmacy.  
Polypharmacy in the elderly has been correlated with increased age,[2,5] and 
with specific diseases, including cardiovascular diseases, rheumatic diseases and 
respiratory illnesses.[6] Previous studies have also demonstrated that as the 
number of concomitant medications increases in elderly patients, so does the risk 
of adverse drug events.[7-9] Furthermore, polypharmacy has been found to be 
associated with risk of emergency department visits, hospitalizations, hospital 
readmissions and death in the elderly.[7,10,11] The risk of morbidity and mortality 
associated with polypharmacy, combined with the trend of population aging 
worldwide, makes polypharmacy an area of prime concern and a potential target 
for decreasing preventable adverse events. 
Despite being a well recognized problem in the elderly population, a 
universally accepted, formal definition for polypharmacy has yet to be 
established.[1,12] Several studies have categorized polypharmacy into different 
levels based on the number of medications taken.[1,2,13-15] More specific 
definitions quantify polypharmacy by the number of simultaneous medications 
taken by a patient. The definition that is most frequently used is the simultaneous 
use of five or more medications. Based on this definition, prevalence estimates 
for polypharmacy in the outpatient setting vary from 4% to 42% in the elderly 
population.[3-6,16-23]  
While polypharmacy in the elderly has been described in several European 
countries, the literature on the topic in Italy is scant. The availability of a large, 
linkable outpatient pharmacy database in Emilia-Romagna, Italy, a large northern 
region with a population of about 4 million inhabitants, provides an excellent 
opportunity to evaluate the prevalence of polypharmacy in the elderly and to 
determine patient characteristics that are predictive of exposure. 
 
Methods 
The study protocol was approved by the Institution Review Board of Thomas 
Jefferson University, Philadelphia, Pennsylvania, USA.  
Study Design and Population 
We conducted a retrospective cohort study of medication use in the elderly 
using the Emilia-Romagna outpatient prescriptions database from January 1, 
2007 to December 31, 2007. This database includes all medications reimbursed 
by the 2007 National Pharmaceutical Formulary (PFN, Prontuario Farmaceutico 
Nazionale).1 The characteristics of the database have been described 
elsewhere.[24] We linked prescription claims in the pharmacy database with data 
from a 2007 demographic file of 960 359 elderly Emilia-Romagna residents 
                                                     
1 The PFN includes all medications marketed in Italy. It has a positive and a 
negative drug list, outlining which medicines will be reimbursed and which need 
to be paid for in full by patients, respectively. All essential medications, such as 
cardiovascular and antihyperglycaemic drugs, are reimbursed by the PFN; non-
essential medications such as benzodiazepines, as well as any over-the-counter 
medications such as antitussive and cold drugs, are not reimbursed. All Italian 
citizens are entitled to access essential healthcare services, including PFN-
reimbursed medications. 
(aged ≥65 years as at January 1, 2007).2 The study cohort was comprised of 
887 165 elderly subjects who had at least one prescription filled during the study 
year (92.3% of the Emilia-Romagna elderly population).  
 
Study Definitions and Measures 
For the purposes of this study we defined polypharmacy as the simultaneous 
use of five or more medications, a definition that has been widely used in 
previous studies.[3,13,18,19,23,25] Medications were classified using the Anatomical 
Therapeutic Chemical (ATC) classification index, and were further differentiated 
to the fifth level of classification (e.g. B01AA03 represents warfarin).[26] 
Duration of therapy was calculated assuming that daily drug intake was equal to 
the defined daily dose (DDD), as determined by the WHO.[26] In addition, it was 
assumed that subjects completed the duration of therapy for all filled 
prescriptions. Treatment was assumed to have begun on the day that the 
prescription was filled. The number of drugs taken on each day of the year was 
then calculated for each subject, and occurrence of polypharmacy was tabulated 
from this information. 
One-year prevalence was defined as the number of individuals who had at least 
one episode of polypharmacy during the study period. Subjects exposed to 
polypharmacy were also stratified by the total number of days of exposure. 
Incidence of polypharmacy was determined using a method previously described 
by Bjerrum et al.[13] Subjects with first-time polypharmacy occurrence were 
identified for each month. As such, elderly exposed to polypharmacy for the first 
time in the final 3 months of 2007 were assumed to represent true incident cases. 
The mean monthly first-time occurrence during the final 3 months of 2007 was 
assumed to represent the monthly incidence of polypharmacy.  
 
Subject Characteristics 
Information on subjects’ age, sex and geographic location was retrieved from 
the demographic file. Level of co-morbid disease was calculated using the 
Chronic Condition Drug Group (CCDG) score. The CCDG score classifies up to 
31 chronic conditions based on consumption of specific medications.[27] The 
CCDG score for an individual reflects the extent to which a person is affected by 
                                                     
2 Because of the reimbursement process, information in the Emilia-Romagna 
pharmacy database is very accurate. The pharmacy database includes a unique, 
anonymous patient identification number, which has been used to link the 
pharmacy database with the demographic file. The linkage between the 
demographic file and the pharmacy database was virtually complete. 
chronic conditions (i.e. higher CCDG scores reflect a higher number of chronic 
conditions). 
 
Data Analysis 
The unit of analysis for the study was the individual subject. Descriptive 
statistics were generated for all variables of interest. A bivariate analysis was 
used to compare the characteristics of drug users exposed to polypharmacy and 
those not exposed using chi-squared (χ2) tests for categorical variables. A 
multivariable logistic regression analysis was used to identify factors that were 
predictive of polypharmacy exposure. Subject characteristics that were 
incorporated in our model as independent variables included sex 
(dichotomously), age (categorically) and geographic location (categorically). The 
CCDG score was not included in our model because in a separate analysis it was 
shown to be correlated with the number of medications a subject received (r = 
0.71), and hence inherently correlated with polypharmacy. A p-value <0.05 was 
considered significant for all analyses. All data analysis was completed using 
SAS® version 9.1 (SAS Institute Inc., Cary, NC, USA). 
 
 
 
Results 
Subject Characteristics and Medication Use 
Of the 887 165 elderly drug users in the region, the mean ± SD age of the study 
population was 75.5 ± 7.5 years. Females made up 58.3% of the study population 
(table I). The mean ± SD number of distinct medications (i.e. having different 
ATC codes) taken during the study period was 6.3 ± 4.2. Total per-patient drug 
utilization during the study period was as follows: 39.3% used between one and 
four distinct drugs, 28.4% used between five and seven drugs, 17.4% used 
between eight and ten drugs, 10.2% used between eleven and fourteen drugs and 
4.7% used fifteen or more drugs.  
Table I 
 
Prevalence of Polypharmacy 
Of the elderly drug users in the region, 349 689 (39.4%) had at least one 
episode of polypharmacy exposure during the study period (table I). People 
exposed to polypharmacy were more likely to be older male and have a higher 
number of co-morbidities. Approximately one-third (36.1%) of elderly exposed 
to polypharmacy were prescribed 11 or more distinct medications in the study 
period. Of those exposed to polypharmacy, 47.6% were exposed for a total of 
≤50 days, 16.8% for 51–100 days, 20.1% for 101–200 days and 15.5% for ≥200 
days. 
All of the following drug classes were used by more than one-third of subjects 
exposed to polypharmacy: antithrombotics; peptic ulcer disease and gastro-
oesophageal reflux disease agents; ACE inhibitors; antihyperlipidaemic agents; 
β-adrenoceptor antagonists; and NSAIDs (table II).  
Table II 
 
Incidence of Polypharmacy 
 Figure 1 shows the number of individuals exposed to polypharmacy for each 
month of the study period according to the month in which the first episode of 
polypharmacy occurred. The mean monthly occurrence of new exposures to 
polypharmacy in the last 3 months of the study period was 11 235. Therefore, the 
estimated incidence of subjects exposed for the first time to polypharmacy was 
1.3% per month.  
Fig. 1 
 
Logistic Regression Analysis 
The multivariable logistic regression analysis demonstrated that age, sex and 
geographic location were correlated with exposure to polypharmacy (table III). 
Using subjects aged 65–74 years as the referent group, risk of exposure to 
polypharmacy increased as age increased (odds ratios [OR] 1.76 for age 75–84 
years and OR 1.83 for age ≥85 years). The odds of exposure were lower in 
females than males (OR 0.85). Finally, there was a slightly lower risk of 
polypharmacy exposure for patients in rural areas (hill and mountain locations; 
OR 0.98 and 0.96, respectively) than in urban areas (plain location).  
Table III 
 
 
 
Discussion 
To our knowledge, this is the first large, population-based study documenting 
the prevalence of polypharmacy in Italy. The evidence generated by this 
investigation supports three main conclusions. First, we noted that a large 
number of elderly subjects in Emilia-Romagna are exposed to polypharmacy. 
Second, we observed that new exposures to polypharmacy occur at a consistent 
rate and affect a significant number of elderly subjects. Third, our evidence 
demonstrated that a large number of the polypharmacy exposures extend over a 
long period of time. Taken as a whole, these findings are cause for concern for 
both practitioners and healthcare policy decision makers in Emilia-Romagna 
because of the correlation that has been demonstrated between polypharmacy and 
inappropriate prescribing in this population.[28] Additional research is needed to 
determine if, and to what extent, this phenomenon exists in other regions of Italy. 
The data used in our study afford us confidence that the results generated are an 
accurate reflection of the patterns of medication use by the elderly in Emilia-
Romagna. Other polypharmacy studies frequently rely on pharmacy data 
collected upon patient admission to and/or discharge from a hospital,[29] during 
patient interactions with data collectors (either at home, over the phone or in an 
office setting)[4,5,8,14,30-32] or from patient and/or physician recall,[3] all of which 
are methods that leave room for inaccuracies in data collection. Because the 
outpatient pharmacy database used in our study was initially collected at the site 
of dispensation and was used for reimbursement purposes, the data used in our 
study have a much lower likelihood of containing error.  
We found the prevalence of polypharmacy in our study cohort of elderly 
patients to be 39.4%. This prevalence falls in the high end of the range reported 
in previous studies conducted in outpatient settings that used the same definition 
of polypharmacy (4–42%).[3,6,16-19,23] While some of the variability in the reported 
prevalence among studies is undoubtedly due to variations in clinician practices 
and patient behaviours in different countries, it may also be a result of differences 
in the sample age,[3,4,16,17] the nature of the data source[3,16-19] and the units of 
analysis.[6,18,23] Thus, comparisons between polypharmacy studies can be 
extremely cumbersome and difficult to interpret. Despite the challenges faced in 
comparing polypharmacy investigations, it is clear that polypharmacy is a 
significant problem in the elderly and warrants additional attention. Further 
research in this area may help to determine the necessity and most appropriate 
mechanism for interventions tailored to the needs of different countries and 
populations. 
As was expected, our results show that as the number of chronic conditions 
increases, so does polypharmacy exposure. Clearly, patients with multiple 
chronic conditions must be treated with appropriate pharmacotherapy. For 
example, a patient with non-insulin dependent (type II) diabetes mellitus must be 
treated with at least one medication, and often multiple medications, to manage 
this chronic disease. If this patient also has hypertension and hyperlipidaemia, 
then it is quite likely that appropriate treatment of these conditions would result 
in exceeding the polypharmacy threshold. For this reason, it is challenging to 
determine, based on the number of chronic conditions alone, whether or not the 
exposure to polypharmacy is appropriate. Future research exploring how the 
presence of chronic conditions affects health outcomes may help uncover when 
interventions to address polypharmacy would be beneficial. 
Our multivariable analysis showed that older age, male sex and geographic 
location were significantly associated with the risk of exposure to polypharmacy. 
The correlation between polypharmacy exposure and increased age is supported 
by previous literature.[2,5] Our findings reinforce these reports. This association is 
of considerable concern because of the implications of overuse of medications in 
the elderly. Predisposing factors in the elderly, such as the decline in renal 
function that accompanies the aging process,[33] increase the potential for drug-
drug and/or drug-disease interactions, drug toxicities and other adverse drug 
events.  
In our study, males were found to be more likely to be exposed to 
polypharmacy. We found only one other study that reported a positive correlation 
between male sex and polypharmacy exposure.[34] Conversely, many studies have 
reported a correlation between polypharmacy and female sex.[4-6,14,30] Such 
discrepancies among study findings could be due to differences in physicians’ 
prescribing attitude toward sexes, as well as to differences between sexes in 
educational and socioeconomic characteristics.[35] Further research exploring the 
relationship between sex and polypharmacy is warranted.  
Elderly living in urban areas (plain locations) were found to be more likely to 
be exposed to polypharmacy than those living in rural areas (hill and mountain 
locations). One possible explanation for this result may be that providers 
practicing in urban areas differ in their characteristics and, as a result, in their 
prescribing patterns. There is evidence that provider attributes, such as sex, and 
practice characteristics, including structure and workload, are predictive of 
polypharmacy exposure in their patients.[36] However, information on provider 
and practice characteristics was not available in our database. Future research 
exploring the relationship between polypharmacy and provider characteristics 
may be of interest.  
The presence of antithrombotics and NSAIDs among the drug categories 
commonly used by elderly people exposed to polypharmacy is of great concern 
because of the potential for adverse drug events with these agents. 
Antithrombotics such as warfarin have a narrow therapeutic window and a high 
number of drug-drug interactions that put these patients at risk.[37,38] In addition, 
NSAIDs are found on published lists of medications to be avoided in the elderly 
because of the high number of NSAID related adverse events and potential drug 
interactions in this population.[28,39,40]  
Several of the medication classes that were identified as commonly used by 
patients exposed to polypharmacy in our study have also been reported in 
previous investigations.[2,5,6,8,22] Bjerrum et al.[6] reported that elderly patients 
exposed to polypharmacy frequently used cardiac therapies and analgesics 
(including NSAIDs). Flaherty et al.[8] reported that gastrointestinal agents and 
ACE inhibitors were among the most frequently used medications in a cohort of 
older patients discharged from a home care agency. Knowledge of medication 
classes that are commonly part of polypharmacy regimens may assist physicians 
in identifying elderly patients for whom particular attention should be paid when 
reviewing the appropriateness, safety and efficacy of their drug therapy. 
Limitations 
Our study has several limitations. First, we cannot say with certainty whether or 
not prescribed medicines were actually used by patients. Next, we used DDDs to 
estimate the duration of therapy for each prescription in order to determine 
overlapping of treatments and therefore identify polypharmacy exposures. The 
WHO Collaborative Centre for Drug Statistics and Methodology defines the 
DDD as “the assumed average maintenance dose per day for a drug used for its 
main indication in adults.”[41] DDD is a useful estimator for calculating durations 
of treatment.[42] However, substantial differences may exist between the doses 
determined using DDDs and the actual prescribed dose. This may be particularly 
true for drugs such as antithrombotics, which require individualized dosing for 
each patient because of the narrow therapeutic window. In addition, the elderly 
may require more frequent dosage adjustments because of issues such as renal 
and hepatic impairment. Because each prescription is tailored to the patient’s age, 
sex, weight and other factors that may affect the drug’s pharmacokinetics and 
pharmacological activity, DDDs provides only a rough estimate of the duration 
of therapy. It is possible that some misclassification of polypharmacy occurred, 
but this is not likely to have substantially impacted our results.  
The Emilia-Romagna database does not include prescription medications not 
reimbursed by the PFN, such as benzodiazepines, or any non-prescription 
medications such as over-the-counter medications, herbal remedies or dietary 
supplements. A correlation between non-prescription medication use and 
polypharmacy in the elderly has been reported in the literature.[3] These 
treatments also carry the risk of interactions and adverse events,[43-46] and 
therefore are relevant in the discussion of polypharmacy. For these reasons, it is 
reasonable to conclude that our results are a conservative estimate of the true 
prevalence of polypharmacy in Emilia-Romagna.  
The use of CCDG scores as a proxy for patient co-morbidities is a viable 
method but has its limitations. There are some diseases that have no 
pharmacological treatment and are therefore not accounted for in the CCDG 
score. In addition, many medications may be used for the treatment of more than 
one disease. It may therefore be impossible to differentiate whether the use of 
one medication, in a patient taking multiple medications, is for the treatment of a 
separate co-morbidity or is part of a multi-drug regimen for a single disease. 
While it is not possible for us to know whether we more frequently over-
estimated or under-estimated the CCDG scores, it is likely that these errors 
cancelled each other out in the aggregate.  
 
 
 
Conclusions 
Our study results add to the growing evidence that a significant proportion of 
the elderly are exposed to polypharmacy. However, it is important to emphasize 
that polypharmacy is not synonymous with inappropriate treatment. Many elderly 
patients who are taking more than five medications may have appropriate 
indications for all of these therapies and may lack any major risk for adverse 
events, such as drug-drug or drug-disease interactions. However, the risk of these 
adverse events increases as the number of medications that a patient takes 
simultaneously increases. Therefore, it is highly desirable that physicians identify 
and keep under surveillance patients exposed to polypharmacy. Raising 
awareness of the characteristics of those elderly most likely to be exposed to 
polypharmacy, in conjunction with studies describing the risks associated with 
increased medication use in this population, may help to ensure safe, effective 
and appropriate use of medication in the elderly. 
In summary, our analysis found that the prevalence of polypharmacy exposure 
in the elderly population of Emilia-Romagna is of great magnitude. Several 
factors that may be used to screen patients for risk of polypharmacy exposure 
were identified. This study provides clinicians in the region with information that 
they may use to improve the quality of care provided to their elderly patients.  
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Fig. 1. Proportion of subjects exposed to polypharmacy for the first time by 
month during 2007. Elderly exposed to polypharmacy for the first time in the 
final 3 months of 2007 (see grey bars) were assumed to represent true incident 
cases, as per the method described by Bjerrum et al.[13] Thus, the mean monthly 
first-time occurrence during the final 3 months of 2007 was assumed to represent 
the monthly incidence of polypharmacy. 
 
Table I. Bivariate comparison of characteristics of the patients according to 
exposure to polypharmacy 
Characteristic Subjects not exposed to 
polypharmacy (n = 537 476) 
Subjects exposed to 
polypharmacy (n = 349 689) 
 n % n % 
Age (y)* 
65–74 294 354 54.8 142 921 40.9 
75–84 181 100 33.7 153 227 43.8 
≥85  62 022 11.5  53 541 15.3 
Sex  
Female 318 931 59.3 198 438 56.7 
Male 218 545 40.7 151 251 43.3 
Geographic location* 
Mountain 
(rural) 
 29 497  5.5  19 140  5.5 
Hill (rural)  148 786 27.7  96 101 27.5 
Plain (urban) 359 193 66.8 234 448 67.0 
CCDG score*  
0–1 293 485 54.6  20 422  5.8 
2–3 230 183 42.8 187 502 53.6 
≥4  13 808  2.6 141 765 40.5 
No. of drugs prescribed*  
1–4 348 405 64.8   
5–7 150 670 28.0 101 452 29.0 
8–10  32 590  6.1 122 162 34.9 
11–14   5 481  1.0  85 042 24.3 
≥15     330  0.1  41 033 11.7 
CCDG = Chronic Condition Drug Group; * p < 0.05. 
 
Table II. Anatomical Therapeutic Chemical (ATC)[26] level 3 drug classes most 
frequently used by subjects exposed to polypharmacy 
ATC 
class 
(level 3) 
Description Female 
(n = 
198 438) 
[%] 
Male 
(n = 
151 251) 
[%] 
All 
(n = 
349 689) [%] 
B01A Antithrombotics 65.8 75.9 70.1 
A02B PUD and GERD agents 50.0 46.6 48.5 
C09A ACE inhibitors 34.1 41.9 37.5 
C10A Antihyperlipidaemics 34.8 40.9 37.4 
C07A β-adrenoceptor 
antagonists 
35.5 39.0 37.0 
M01A NSAIDs 41.3 28.8 35.9 
C03C High-ceiling diuretics 31.7 32.0 31.8 
C08C Selective calcium 29.7 32.1 30.8 
channel antagonists 
N06A Antidepressants 27.3 15.9 22.4 
C01D Vasodilators 18.4 22.9 20.3 
R03B Non-adrenergic inhalers 17.1 21.0 18.8 
A10B Antihyperglycaemics 
(excluding insulin) 
17.2 19.8 18.3 
C09C ARBs 18.2 16.5 17.5 
C09B ACE inhibitor 
combination products 
17.0 15.5 16.4 
R03A Adrenergic inhalers 14.3 18.2 16.0 
C09D ARB combination 
products 
17.4 13.0 15.5 
G04C BPH products  0.2 32.6 14.2 
S01E Antiglaucoma 
preparations and miotics 
12.5 11.2 11.9 
C01B Antiarrhythmics, class I 
and III 
 6.7  8.1  7.3 
A10A Insulin and analogues  3.9  4.0  3.9 
ARB = angiotensin II type 1 receptor antagonist (angiotensin receptor blocker); 
BPH = benign prostatic hyperplasia; GERD = gastro-oesophageal reflux disease; 
PUD = peptic ulcer disease. 
 
Table III. Multivariable logistic regression of patient characteristics associated 
with polypharmacy exposure 
Characteristic Odds ratio 95% CI 
Age (y) 
65–74 1.00 Referent 
75–84 1.76 1.74, 1.78*  
≥85 1.83 1.80, 1.85* 
Sex 
Male 1.00 Referent 
Female 0.85 0.846, 0.861* 
Geographic location 
Plain (urban) 1.00 Referent 
Hill (rural) 0.98 0.97, 0.98* 
Mountain (rural) 0.96 0.94, 0.98* 
* p < 0.05 vs referent. 
 
 
 
